Severe asthma in obese patients: Improvement of lung function after treatment with omalizumab

This was a non-interventional, prospective study that examined the impact of omalizumab in 32 obese and non-obese patients with poorly controlled severe persistent asthma. Pulmonary function endpoints included FEV1 and FVC, and were measured using the Vitalograph Pneumotrac spirometer.